Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT04363164
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Castration Resistant Metastatic Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 90 years
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Last updated on ClinicalTrials.gov
- July 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California, San Diego (UCSD) · San Diego, CA
Maryland · 1
- Johns Hopkins University/Sidney Kimmel Cancer Center · Baltimore, MD
Massachusetts · 1
- Dana-Faber Cancer Institute · Boston, MA
Minnesota · 1
- University of Minnesota · Minneapolis, MN
Nebraska · 1
- University of Nebraska Medical Center · Omaha, NE
Washington · 1
- University of Washington/Fred Hutchinson Cancer Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.